Revolution Medicines, Inc. (RVMD)
UndervaluedFundamental
30
Price
$186.99
Market Cap
$41.64B
Part 1 · What the company is worth
Overview
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
0
Fiscal year ended 12/31/2025
Net Income
$-1.13B
Fiscal year ended 12/31/2025
Free Cash Flow
$-914M
Total Equity
$1.63B
Total Liabilities
$723M
Current Ratio
11.38
Interest Coverage
27.42
Debt/EBITDA
-
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
No income data available
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$257.53
Current Price
$186.99
Margin of Safety
+27.4%
Fair Value Range
$244.65 - $270.41
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
-
ROE
-69.3%
P/B Ratio
15.38
P/FCF
-
Gross Margin
-
ROIC
-32.4%
Profitability Radar
Value Creation (Economic Moat)
ROIC
-32.4%
WACC
12.0%
ROIC − WACC
-44.4 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (6)
- EPS shows upward trend
- Price CAGR 29.54%
- Debt/equity ratio
- Current ratio
- Interest coverage
- Low reliance on intangibles
Failed (10)
- ROIC -32.4%
- P/B ratio 15.38
- Operating margin -Infinity%
- Positive free cash flow
- Return on tangible assets
- DCF valuation (Unknown)
- ROE -54.1%
- Earnings surprise, average -25.1%
- Share dilution 13.4%
- Piotroski F-Score 1/9
Unavailable (10)
- Gross margin –
- P/FCF –
- Dividend payout –
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- Revenue growth 5Y
- PEG ratio (needs P/E > 0 and growth > 0)
- Earnings quality (operating cash flow / net income)
- Net margin trend (invalid data)
Piotroski F-Score
Serious financial concerns
Earnings Quality
Low quality: investigate accounting
Share Dilution
Issuing new shares, diluting ownership
Institutional Holdings
Well-known investors who own Revolution Medicines, Inc.
Latest 13F: quarter ended 06/30/2026
| Investor | Weight in their portfolio | Last quarter |
|---|---|---|
| Stanley Druckenmiller · Duquesne Family Office | 1.7% | +$15.7K |
| Joel Greenblatt · Gotham Asset Management | 0.1% | -$973.7K |
Source: 13F filings with the SEC. Long positions in US stocks only, filed up to 45 days late.
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Dr. Mark A. Goldsmith M.D., Ph.D. | CEO, President & Chairman | 63 |
| Mr. Jack Anders | Chief Financial Officer | 48 |
| Ms. Margaret A. Horn J.D. | Chief Operating Officer | 62 |
| Mr. Jeffrey Cislini J.D. | Senior VP, General Counsel & Corporate Secretary | 50 |
| Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. | Senior Advisor | 64 |
| Dr. Martin D. Burke M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | - |
| Dr. Michael A. Fischbach Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | 44 |
| Dr. Kevan M. Shokat Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | - |
| Mr. Walter Reiher Ph.D. | Chief Information Officer | - |
| Ms. Jan Smith Ph.D. | Chief Scientific Officer | - |
Audit Risk
2
Board Risk
7
Compensation Risk
8
Shareholder Rights Risk
8
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-25
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-08-05
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-10-13
via SEC EDGAR
Income History
via SEC EDGAR
Part 2 · The price and its context
This part shows how the price has behaved, not whether the company is worth owning. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Market Reaction Profile
How much RVMD moves, measured on its daily prices.
More volatile than 62% of the tracked stocks (90-day volatility).
- Volatility 30d
- 47.7%
- Volatility 90d
- 41.2%
- Beta vs S&P 500 (1y)
- 1.19Correlation 0.23
- Max drawdown (12m)
- -25.0%
- ATR (14d, % of price)
- 4.93%
Earnings reactions
How RVMD moved around its past quarterly results.
Next earnings release
Nov 4, 2026 · In 10 days · Time not known
EPS estimate: -2.38Revenue estimate: $27M
What usually happens
- Over the last 12 releases the stock moved a median of 1.7% the next day, up or down.
- Next-day moves: up 4, down 8 (out of 12).
Release history
| Date | When | EPS est. | EPS actual | Surprise | Gap | 1 day | 5 days |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026 | After the close | -2.02 | -3.06 | -51.7% | +0.2% | +0.3% | +4.0% |
| May 6, 2026 | After the close | -1.88 | -2.29 | -22.1% | -1.5% | -5.7% | -0.7% |
| Feb 25, 2026 | After the close | -1.61 | -1.86 | -15.4% | -7.5% | -1.1% | -2.0% |
| Nov 5, 2025 | After the close | -1.45 | -1.61 | -11.2% | +0.7% | +3.4% | +10.9% |
| Aug 6, 2025 | After the close | n/a | n/a | n/a | -6.8% | -4.7% | -1.6% |
| May 7, 2025 | After the close | n/a | n/a | n/a | +8.3% | +11.3% | +4.8% |
| Feb 26, 2025 | After the close | n/a | n/a | n/a | -1.5% | -3.5% | -2.2% |
| Nov 6, 2024 | After the close | n/a | n/a | n/a | -2.4% | -0.5% | -2.2% |
| Aug 7, 2024 | After the close | n/a | n/a | n/a | -5.1% | -0.7% | +0.7% |
| May 8, 2024 | After the close | n/a | n/a | n/a | +2.5% | -2.2% | +2.8% |
| Feb 26, 2024 | After the close | n/a | n/a | n/a | +4.1% | +0.8% | -2.9% |
| Nov 6, 2023 | After the close | n/a | n/a | n/a | -0.9% | -0.2% | -8.8% |
Release dates from SEC 8-K filings.
Updated 10/25/2026
Historical statistics for educational purposes only. They are not forecasts and not investment advice.
Latest News
Recent headlines for RVMD.
- 8/27/2026POSITIVERevMed’s Pancreatic Cancer Pill Priced Above $475K per Year
Revolution Medicines has secured US approval for Rasonque, a novel pill targeting advanced pancreatic cancer, a significant breakthrough in treating a notoriously difficult tumor type. The drug, priced at over $475,000 annually, is among the most expensive cancer therapies developed. Its broad targeting of the RAS protein, a key driver in most pancreatic cancers, offers a new therapeutic avenue. This approval marks a substantial advancement in oncology, potentially improving patient outcomes and establishing a new standard of care for this challenging disease.
- +1 day
- -5.8%
- +3 days
- -3.9%
- 6/1/2026POSITIVERevolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs
Revolution Medicines announced a significant breakthrough in pancreatic cancer treatment, with its experimental pill demonstrating a doubling of patient survival rates and a 60% reduction in the risk of death during clinical trials. This development is particularly noteworthy given the historically poor prognosis associated with pancreatic cancer. The positive trial results suggest a potential paradigm shift in treatment options for this aggressive disease. For investors, this news could translate into substantial future revenue streams and a re-evaluation of the company's growth prospects, especially as the stock is currently trading near its all-time highs.
- +1 day
- +3.7%
- +3 days
- -0.7%
- 4/13/2026POSITIVERevolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus Chemo
Revolution Medicines Inc. stock surged following promising Phase 3 trial results for its pancreatic cancer drug, darsonvalrasib. The study demonstrated a doubling of survival rates compared to standard chemotherapy, a significant breakthrough for patients with KRAS G12C-mutated pancreatic cancer. The company announced plans for regulatory filings, signaling a clear path toward potential market approval. This development is highly encouraging for investors, suggesting a strong future revenue stream and a significant advancement in oncology treatment.
Published while the US market was open: the move of that day cannot be split into before and after the news, so no figure is shown.
- 2/25/2026NEUTRALRevolution Medicines (RVMD) Earnings Transcript
Revolution Medicines (RVMD) has released its earnings transcript, although the specific content is not yet available for analysis. Investors are keenly awaiting the details of this publication, which could provide clarity on the company's financial performance and future outlook. The absence of immediate information prevents a directional assessment, keeping the stock in a holding pattern. It will be crucial to monitor the data as soon as it is disclosed to understand the impact on research and development, product pipeline, and market strategies, which are fundamental elements for evaluating RVMD's growth potential in the biopharmaceutical sector.
Return of the stock minus return of SPY over the same days. A news item close to a price move did not necessarily cause it. Historical data for educational purposes only, not investment advice.